Table 4 Phase 1 and early phase 1 bispecific antibodies (BiTE), antibody–drug conjugates (ADC), and monoclonal antibodies (MoAb) for RRMM, as of December 31, 2020, with study start date after January 1, 2019
From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Target antigens | Product name (NCT) | Study sponsor | Estimated enrollment | Country |
|---|---|---|---|---|
Bispecific antibodies (BiTE) | ||||
BCMA × CD3 | REGN5459 (NCT04083534) | Regeneron | 56 | United States |
BCMA × CD3 | TNB-383B (NCT03933735) | Teneobio | 72 | United States |
BCMA × CD3 × albumin (“tri-specific”) | HPN217 (NCT04184050) | Harpoon | 70 | United States |
BCMA × CD16a | RO7297089 (NCT04434469) | Genentech | 80 | Australia, Denmark, Norway |
CD28/38 × CD3 | SAR442257 (NCT04401020) | Sanofi | 57 | United States |
GPRC5D × CD3 and BCMA × CD3 | Talquetamab and teclistamab (NCT04108195) | Janssen | 100 | United States, Canada, Germany, the Netherlands, Spain |
Antibody–drug conjugates (ADC) | ||||
BCMA, monomethyl auristatin-F [59] | GSK2857916 (belantamab mafodotin) (NCT03828292) | GlaxoSmithKline | 14 | Japan |
BCMA, maytansinoid | CC-99712 (NCT04036461) | Celgene | 120 | United States, Canada |
BCMA, Shiga-like toxin-A subunit (engineered toxin bodies) [21] | TAK-169 (NCT04017130) | Millennium Takeda | 102 | United States |
CD46, monomethyl auristatin-F [60] | FOR46 (NCT03650491) | Fortis | 50 | United States |
Monoclonal antibodies (MoAb) | ||||
CD38 | SAR442085 (NCT04000282) | Sanofi | 78 | United States, France, Spain |
CD47 | AO-176 (NCT04445701) | Arch Oncology | 102 | United States |
IL-18 | AEVI-007 (NCT04671251) | Aevi/Cerecor | 30 | United States |